JP2024178420A5 - - Google Patents
Info
- Publication number
- JP2024178420A5 JP2024178420A5 JP2024167085A JP2024167085A JP2024178420A5 JP 2024178420 A5 JP2024178420 A5 JP 2024178420A5 JP 2024167085 A JP2024167085 A JP 2024167085A JP 2024167085 A JP2024167085 A JP 2024167085A JP 2024178420 A5 JP2024178420 A5 JP 2024178420A5
- Authority
- JP
- Japan
- Prior art keywords
- lou064
- administered
- treatment
- interferon
- multiple sclerosis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (12)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163240444P | 2021-09-03 | 2021-09-03 | |
| US63/240,444 | 2021-09-03 | ||
| US202163282363P | 2021-11-23 | 2021-11-23 | |
| US63/282,363 | 2021-11-23 | ||
| US202263304106P | 2022-01-28 | 2022-01-28 | |
| US63/304,106 | 2022-01-28 | ||
| US202263353866P | 2022-06-21 | 2022-06-21 | |
| US63/353,866 | 2022-06-21 | ||
| US202263369008P | 2022-07-21 | 2022-07-21 | |
| US63/369,008 | 2022-07-21 | ||
| PCT/IB2022/058205 WO2023031840A1 (en) | 2021-09-03 | 2022-09-01 | Lou064 for treating multiple sclerosis |
| JP2023517239A JP7564347B2 (ja) | 2021-09-03 | 2022-09-01 | 多発性硬化症を治療するためのｌｏｕ０６４ |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517239A Division JP7564347B2 (ja) | 2021-09-03 | 2022-09-01 | 多発性硬化症を治療するためのｌｏｕ０６４ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024178420A JP2024178420A (ja) | 2024-12-24 |
| JP2024178420A5 true JP2024178420A5 (https=) | 2025-09-08 |
Family
ID=83438454
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517239A Active JP7564347B2 (ja) | 2021-09-03 | 2022-09-01 | 多発性硬化症を治療するためのｌｏｕ０６４ |
| JP2024167085A Pending JP2024178420A (ja) | 2021-09-03 | 2024-09-26 | 多発性硬化症を治療するためのｌｏｕ０６４ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023517239A Active JP7564347B2 (ja) | 2021-09-03 | 2022-09-01 | 多発性硬化症を治療するためのｌｏｕ０６４ |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240350489A1 (https=) |
| EP (1) | EP4395779A1 (https=) |
| JP (2) | JP7564347B2 (https=) |
| KR (1) | KR20240055038A (https=) |
| AU (1) | AU2022337087A1 (https=) |
| CA (1) | CA3229887A1 (https=) |
| IL (1) | IL310975A (https=) |
| MX (1) | MX2024002581A (https=) |
| TW (1) | TW202310841A (https=) |
| WO (1) | WO2023031840A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021398051A1 (en) | 2020-12-10 | 2023-07-27 | Principia Biopharma Inc. | Crystal form of tolebrutinib, preparation method therefor and use thereof |
| US20260027100A1 (en) * | 2022-05-13 | 2026-01-29 | Principia Biopharma Inc. | Therapeutic tyrosine kinase inhibitors for myelin oligodendrocyte glycoprotein antibody disease (mogad) |
| CA3260242A1 (en) * | 2022-06-24 | 2023-12-28 | Merck Patent Gmbh | TREATMENT REGIMEN FOR AUTOIMMUNE AND INFLAMMATORY DISEASES |
| US20250243170A1 (en) * | 2024-01-26 | 2025-07-31 | Novartis Ag | Remibrutinib drug substance and drug product substantially free of nitrosamine impurity |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130197080A1 (en) * | 2010-08-02 | 2013-08-01 | Sanofi | Use of teriflunomide for treating multiple sclerosis |
| US9512084B2 (en) | 2013-11-29 | 2016-12-06 | Novartis Ag | Amino pyrimidine derivatives |
| EP3738084A4 (en) * | 2018-01-08 | 2021-11-17 | G1 Therapeutics, Inc. | SUPERIOR G1T38 DOSING SCHEMES |
| CN117285467A (zh) * | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| RS67141B1 (sr) | 2019-05-23 | 2025-09-30 | Novartis Ag | Inhibitor brutonove tirozin kinaze za upotrebu u lečenju hronične spontane urtikarije |
| CN113840821A (zh) | 2019-05-23 | 2021-12-24 | 诺华股份有限公司 | Btk抑制剂的晶型 |
| BR112021023110A2 (pt) | 2019-05-23 | 2022-04-12 | Novartis Ag | Métodos de tratamento de síndrome de sjögren com o uso de um inibidor de tirosina quinase de bruton |
| WO2022081512A1 (en) * | 2020-10-12 | 2022-04-21 | Synubi Pharmaceuticals Llc | Compositions and methods of treatment of neuroinflammatory diseases with bruton's tyrosine kinase inhibitors |
| MX2023008671A (es) * | 2021-01-26 | 2023-09-25 | Novartis Ag | Composicion farmaceutica. |
| BR112023017648A2 (pt) * | 2021-03-03 | 2023-11-14 | Janssen Pharmaceutica Nv | Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk |
-
2022
- 2022-09-01 JP JP2023517239A patent/JP7564347B2/ja active Active
- 2022-09-01 US US18/685,551 patent/US20240350489A1/en active Pending
- 2022-09-01 CA CA3229887A patent/CA3229887A1/en active Pending
- 2022-09-01 KR KR1020247010451A patent/KR20240055038A/ko active Pending
- 2022-09-01 AU AU2022337087A patent/AU2022337087A1/en active Pending
- 2022-09-01 TW TW111133216A patent/TW202310841A/zh unknown
- 2022-09-01 WO PCT/IB2022/058205 patent/WO2023031840A1/en not_active Ceased
- 2022-09-01 EP EP22777001.3A patent/EP4395779A1/en active Pending
- 2022-09-01 IL IL310975A patent/IL310975A/en unknown
- 2022-09-01 MX MX2024002581A patent/MX2024002581A/es unknown
-
2024
- 2024-09-26 JP JP2024167085A patent/JP2024178420A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024178420A5 (https=) | ||
| CA2856646C (en) | Combination treatment of cancer | |
| JP2023088944A5 (https=) | ||
| JP2023510604A5 (https=) | ||
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| JPH0635382B2 (ja) | 抗不安薬としてのフルオキセチンの使用法 | |
| JP2019530648A5 (https=) | ||
| JP2022548575A5 (https=) | ||
| JP2024523559A5 (https=) | ||
| JP2004525940A (ja) | 火照りの処置のためのデュロキセチン | |
| CN102056602A (zh) | 决奈达隆用于预防心脏复律 | |
| JP2024539476A5 (https=) | ||
| JP2023520929A5 (https=) | ||
| US20240299318A1 (en) | Amiselimod for preventing, treating or ameliorating ulcerative colitis | |
| US20040152733A1 (en) | Duloxetine for treatment of hot flashes | |
| JP2000007578A (ja) | Ｃ型肝炎ウイルスの陰性化のための投薬システム | |
| CN115887502A (zh) | 粪副拟杆菌在制备防治心力衰竭药物中的应用 | |
| CN110325214A (zh) | 用于预防和治疗神经元损伤的低剂量药物组合 | |
| Hanssen et al. | Extended Experience with Recombinant a-2b Interferon with OR Without Hepatic Artery Embolization in the Treatment OF Midgut Carcinoid Tumours A preliminary report | |
| CN110507676A (zh) | 包含藻蛋白多糖提取物的组合物及其用途 | |
| JP2012025734A (ja) | 骨髄異形性症候群を治療するための組成物および方法 | |
| JPH10175852A5 (https=) | ||
| HK40094222A (zh) | 预防、治疗或改善溃疡性结肠炎的阿米莫德 | |
| WO2025134072A1 (en) | Methods for preventing, treating, or ameliorating ulcerative colitis in certain patient populations with amiselimod | |
| RU2023131044A (ru) | Эффективная комбинированная терапия против hvc |